Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
CG Oncology bladder cancer immunotherapy cuts tumor recurrence risk by 68% in Phase 3
00

CG Oncology bladder cancer immunotherapy cuts tumor recurrence risk by 68% in Phase 3

Nov 16, 2026

On November 16, 2026, CG Oncology announced that its experimental oncolytic immunotherapy cretostimogene grenadenorepvec reduced the risk of tumor recurrence by 68% in a Phase 3 trial of 367 patients with intermediate-risk non-muscle-invasive bladder cancer. Shares of CG Oncology jumped over 30% in premarket trading following the news. The company expects to present additional trial data in December 2026 and submit an FDA application before the end of March 2027.

Phase 3 trial efficacy and safety results

  • ▪CG Oncology said Cretostimogene grenadenorepvec was generally well tolerated in the Phase 3 trial, with safety results consistent with those reported in previous studies of the immunotherapy
  • ▪In a randomized Phase 3 trial of 367 patients with intermediate-risk non-muscle-invasive bladder cancer following complete tumor resection, CG Oncology's cretostimogene grenadenorepvec reduced the risk of tumor recurrence by 68% compared to current medical practice

Market reaction and commercial outlook

  • ▪Following the announcement of positive Phase 3 trial results on November 16, 2026, CG Oncology shares rose more than 30% to $98 in premarket trading
  • ▪Phase 3 trial success in intermediate-risk non-muscle-invasive bladder cancer potentially expands the commercial market for CG Oncology's cretostimogene immunotherapy asset significantly

Overview and impact of non-muscle-invasive bladder cancer

  • ▪Intermediate-risk non-muscle-invasive bladder cancer is typically removed through minimally invasive surgery, but recurrent tumors over time can compromise bladder function and allow the cancer to grow
  • ▪Standard monitoring for intermediate-risk non-muscle-invasive bladder cancer requires patient evaluations every three months, with repeat surgical procedures performed whenever the cancer recurs
  • ▪Approximately 75% of newly diagnosed bladder cancers are non-muscle-invasive, a form of the disease that can recur and potentially grow into the bladder muscle

3 sources

Endpoints
CG Oncology's bladder cancer treatment beats expectations in Phase 3
View source article
Reuters
CG Oncology's immunotherapy reduces risk of tumor recurrence in bladder cancer trial | Reuters
View source article
STAT News
Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence
View source article

Story comments

Loading comments…

Topics

Cancer immunotherapyCancer & OncologyCancer treatment breakthroughsClinical trialsOncolytic virotherapy